NYCU shares lung therapy data with firms
HOPE?
There are no treatments that can reverse the damage caused by pulmonary fibrosis, but experimental stem cell therapy has helped mice that have the disease
Staff writer, with CNA
A National Yang Ming Chiao Tung University (NYCU) research team has transferred the technology for its experimental stem cell therapy for pulmonary fibrosis to two biotech companies, the first step toward beginning clinical trials, it announced on Friday.
The team led by Fu Yu-show (傅毓秀), a professor in the university’s Institute of Anatomy and Cell Biology, first published details of its therapy, which involves transplanting stem cells collected from umbilical cord fluid into lungs affected by fibrosis, in the international medical journal Theranostics in 2019.